1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915


Delayed Nasdaq Copenhagen  -  10:59 2022-06-30 am EDT
787.20 DKK   -0.18%
06/30NOVO NORDISK A/S : The technical configuration is positive
06/29European ADRs Move Slightly Higher in Wednesday Trading
06/28NOVO NORDISK : UBS lowers its rating to Sell
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S – Share repurchase programme

05/23/2022 | 07:26am EDT

Bagsværd, Denmark, 23 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Under the programme initiated 3 May 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 May 2022 to 2 August 2022.

Since the announcement 16 May 2022, the following transactions have been made:

 Number of
B shares
purchase price
value, DKK
Accumulated, last announcement634,689 487,471,914
16 May 2022100,000742.5774,256,753
17 May 202290,000748.8767,397,920
18 May 2022100,000744.8174,480,694
19 May 202295,000729.0369,257,980
20 May 202285,000751.05763,883,312
Accumulated under the programme1,104,689 836,748,573

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 13,166,381 B shares of DKK 0.20 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 20 May 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 11,426,818 B shares at an average share price of DKK 755.99 per B share equal to a transaction value of DKK 8,638,533,594

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.

Further information

Ambre Brown Morley+45 3079 9289abmo@novonordisk.com
Natalia Salomao Abrahao (US)+1 848 304 1027niaa@novonordisk.com
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
Mark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.com

Company announcement No 47 / 2022


All news about NOVO NORDISK A/S
06/29European ADRs Move Slightly Higher in Wednesday Trading
06/28NOVO NORDISK : UBS lowers its rating to Sell
06/27BNP Paribas Exane Upgrades Novo Nordisk to Neutral From Underperform
06/27Novo Nordisk A/S – Share repurchase programme
06/24NOVO NORDISK : UBS sticks Neutral
06/24NOVO NORDISK : Goldman Sachs keeps its Buy rating
06/23Camp Huronda welcomes back campers for a long-awaited reopening and unveils the new Ins..
06/22Novo Nordisk, Echosens Tie Up to Increase Early Diagnosis of Chronic Metabolic Liver Di..
06/22Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early ..
06/21NOVO NORDISK A/S : Current Report by Foreign Issuer (Form 6-K)
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Sales 2022 168 B 23 642 M 23 642 M
Net income 2022 53 541 M 7 532 M 7 532 M
Net cash 2022 1 841 M 259 M 259 M
P/E ratio 2022 33,3x
Yield 2022 1,47%
Capitalization 1 786 B 251 B 251 B
EV / Sales 2022 10,6x
EV / Sales 2023 9,30x
Nbr of Employees 49 295
Free-Float 69,6%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 787,20 DKK
Average target price 813,00 DKK
Spread / Average Target 3,28%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S7.29%251 273
JOHNSON & JOHNSON3.46%465 732
PFIZER, INC.-11.21%285 819
ROCHE HOLDING AG-15.68%273 835
ABBVIE INC.13.12%272 382